The NSABP B-20 study was performed on a cohort of 651 patients with ER+, node-negative breast cancer from the NSABP B-20 trial. The objective of this study was to determine whether the Recurrence Score result predicted the likelihood of chemotherapy...
Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat. 1993;25:127-9.Rosner D, Lane W. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat 1993;25:127-139....
(2007) 2–47 Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials...
Women with pathologically confirmed clinically node negative T1–2 invasive breast cancer undergoing breast conserving therapy will be randomized for sentinel lymph node biopsy versus no sentinel lymph node biopsy. Endpoints include regional recurrence after 5 (primary endpoint) and 10 years of follow-up...
In 136 cases of nodal-negative breast cancer, the further course regarding the incidence of metastases or recurrence was observe over a period of up to 83 months. Parameters have been tumor size, location, grading, the number of extirpated lymphatic nodules, hormone receptor status, and menopause...
Background:Adjuvant trastuzumab for small, node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains controversial. The purpose of this study was to investigate the risk of recurrence in women with pathological tumour node (pTN) T1 N0 tumours.Methods:Patients with...
Women with pathologically confirmed clinically node negative T1–2 invasive breast cancer undergoing breast conserving therapy will be randomized for sentinel lymph node biopsy versus no sentinel lymph node biopsy. Endpoints include regional recurrence after 5 (primary endpoint) and 10 years of follow-up...
the trial with high-risk features—so the T1 and 0s were excluded, grade 1 patients were excluded—and showing that node-negative, early-stage breast cancer also has risk of recurrence with current standard of care and benefited from the addition of ribociclib to their standard NSAI t...
PURPOSE: To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer. METHODS: We reviewed 965 T1a,bN0M0 breast cancers diagnosed at our institution between 1990 and 2002. Dedicated breast pathol...
摘要: Purpose To evaluate the rate of axillary recurrences in sentinel node (SN) negative breast cancer patients without further axillary lymph node dissection (ALND).关键词:sentinel lymph node biopsy breast neoplasm follow‐up study recurrence ...